• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

斯洛伐克全国宫颈癌有组织筛查开始时高危型人乳头瘤病毒(HPV)感染的发生率。

The incidence of high-risk HPV infections in Slovakia at the start of the national organized screening for cervical cancer.

作者信息

Kudela Erik, Berakova Katarina, Rokos Tomas, Kozubik Erik, Pribulova Terezia, Biringer Kamil, Grendar Marian

机构信息

Clinic of Gynecology and Obstetrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, 03601, Slovakia.

Martinské Bioptické Centrum s.r.o., Zilina, 010 01, Slovakia.

出版信息

Infect Agent Cancer. 2025 Jun 22;20(1):42. doi: 10.1186/s13027-025-00675-x.

DOI:10.1186/s13027-025-00675-x
PMID:40545547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12182681/
Abstract

OBJECTIVE

Until now, Slovakia has lacked complex data regarding the prevalence of specific high-risk HPV types in female population. Accordingly, our study focused on the population of Northern Slovakia, providing valuable insights into the correlation between cytological diagnoses, age, and HPV prevalence.

METHODS

We performed a retrospective analysis of results from cytological cervical cancer screening and HPV DNA testing in 2023 involving 74,850 women in the Zilina region of northern Slovakia.

RESULTS

The most common HPV infection based on the results of the HPV DNA testing was the group positivity for other high-risk HPVs at 17.73%, followed by HPV16 (6.03%) and HPV18 (1.57%) positivity. The overall HPV DNA positivity, regardless of age, was 21.59%. We observed a significant decrease in high-risk HPV prevalence with increasing age ( < 0.001), with the highest values in the age group of 18–25 years (37.92%). A second peak of high-risk HPV infection was observed in the age group of 51–55 years. HPV coinfection, defined as a combination of positive HPV DNA test results, was observed in 3.49% of cases (187/5,354).

CONCLUSION

We found relatively high prevalence of high-risk HPV types in Slovak population. Our findings may serve as a valuable baseline for future evaluations of the impact of both organized screening and vaccination in the country.

摘要

目的

迄今为止,斯洛伐克缺乏关于女性人群中特定高危型人乳头瘤病毒(HPV)流行率的综合数据。因此,我们的研究聚焦于斯洛伐克北部地区的人群,为细胞学诊断、年龄和HPV流行率之间的相关性提供了有价值的见解。

方法

我们对2023年斯洛伐克北部日利纳地区74850名女性的宫颈癌细胞学筛查和HPV DNA检测结果进行了回顾性分析。

结果

根据HPV DNA检测结果,最常见的HPV感染是其他高危型HPV的群体阳性率为17.73%,其次是HPV16阳性率(6.03%)和HPV18阳性率(1.57%)。无论年龄如何,总体HPV DNA阳性率为21.59%。我们观察到高危型HPV流行率随年龄增长显著下降(<0.001),在18 - 25岁年龄组中最高(37.92%)。在51 - 55岁年龄组中观察到高危型HPV感染的第二个高峰。HPV合并感染定义为HPV DNA检测结果呈阳性的组合,在3.49%的病例(187/5354)中观察到。

结论

我们发现斯洛伐克人群中高危型HPV类型的流行率相对较高。我们的研究结果可为该国未来有组织筛查和疫苗接种影响评估提供有价值的基线。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e8/12182681/653d07fce23d/13027_2025_675_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e8/12182681/0dcc3f16da6f/13027_2025_675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e8/12182681/653d07fce23d/13027_2025_675_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e8/12182681/0dcc3f16da6f/13027_2025_675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3e8/12182681/653d07fce23d/13027_2025_675_Fig2_HTML.jpg

相似文献

1
The incidence of high-risk HPV infections in Slovakia at the start of the national organized screening for cervical cancer.斯洛伐克全国宫颈癌有组织筛查开始时高危型人乳头瘤病毒(HPV)感染的发生率。
Infect Agent Cancer. 2025 Jun 22;20(1):42. doi: 10.1186/s13027-025-00675-x.
2
Cytology versus HPV testing for cervical cancer screening in the general population.普通人群宫颈癌筛查中细胞学检查与HPV检测的比较
Cochrane Database Syst Rev. 2017 Aug 10;8(8):CD008587. doi: 10.1002/14651858.CD008587.pub2.
3
The Utility of an Human Papillomavirus Genotype Assay for Cancer Screening in Self-Collected Urine and Vaginal Samples from Japanese Women.人乳头瘤病毒基因分型检测在日本女性自行采集的尿液和阴道样本癌症筛查中的效用
Gynecol Obstet Invest. 2025;90(2):143-152. doi: 10.1159/000541641. Epub 2024 Oct 7.
4
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
5
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.接种人乳头瘤病毒预防性疫苗以预防宫颈癌及其癌前病变。
Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3.
6
Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.Anyplex™ II HPV HR 检测与宫颈癌筛查中参考 HPV 检测的一致性:系统评价。
J Virol Methods. 2022 Mar;301:114435. doi: 10.1016/j.jviromet.2021.114435. Epub 2021 Dec 14.
7
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.在未进行人乳头瘤病毒(HPV)检测的情况下,对于轻度宫颈细胞学异常,立即转诊至阴道镜检查与细胞学监测的比较
Cochrane Database Syst Rev. 2017 Jan 26;1(1):CD009836. doi: 10.1002/14651858.CD009836.pub2.
8
Trends in HPV-positive cervical cancer prevalence: a retrospective study from 2013 to 2020.人乳头瘤病毒(HPV)阳性宫颈癌患病率趋势:一项2013年至2020年的回顾性研究
Virol J. 2025 Jun 18;22(1):199. doi: 10.1186/s12985-025-02830-7.
9
Introduction of the HPV Vaccine among Young Girls to Reduce the Long-Term Risk of Cervical Cancer in Eswatini: Programmatic Decision and Roll Out.在斯威士兰年轻女孩中引入人乳头瘤病毒疫苗以降低宫颈癌长期风险:规划决策与推广
Asian Pac J Cancer Prev. 2025 Jun 1;26(6):1891-1897. doi: 10.31557/APJCP.2025.26.6.1891.
10
Cervical HPV Positivity Elevates the Risk for Oral HPV Infection: A Systematic Review with Meta-Analysis.宫颈人乳头瘤病毒阳性增加口腔人乳头瘤病毒感染风险:一项荟萃分析的系统评价
J Dent Res. 2025 Jun 23:220345251337071. doi: 10.1177/00220345251337071.

本文引用的文献

1
High-risk HPV prevalence in the Czech cervical cancer screening population: a comparison of clinician-collected and self-collected sampling.捷克宫颈癌筛查人群中高危型人乳头瘤病毒的流行情况:临床医生采集样本与自我采集样本的比较
Eur J Public Health. 2025 Aug 1;35(4):760-765. doi: 10.1093/eurpub/ckaf045.
2
Global prevalence of cervical human papillomavirus in women aged 50 years and older with normal cytology: a systematic review and meta-analysis.50岁及以上细胞学正常女性宫颈人乳头瘤病毒的全球流行率:一项系统评价和荟萃分析
Lancet Microbe. 2025 Jan;6(1):100955. doi: 10.1016/j.lanmic.2024.100955. Epub 2024 Nov 29.
3
Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women.
九价人乳头瘤病毒疫苗的长期有效性:斯堪的纳维亚女性 12 年随访的中期结果。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2377903. doi: 10.1080/21645515.2024.2377903. Epub 2024 Oct 7.
4
Patterns of single and multiple HPV infections in female: A systematic review and meta-analysis.女性单一和多重人乳头瘤病毒感染模式:一项系统评价和荟萃分析。
Heliyon. 2024 Aug 18;10(17):e35736. doi: 10.1016/j.heliyon.2024.e35736. eCollection 2024 Sep 15.
5
Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study.意大利 NTCC2 研究中 HPV 阳性分流策略的比较:联合扩展基因分型与细胞学或 p16/ki67 双重染色。
EBioMedicine. 2024 Jun;104:105149. doi: 10.1016/j.ebiom.2024.105149. Epub 2024 May 17.
6
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
7
Divergent effects of switching from cytology to HPV-based screening in the Nordic countries.细胞学筛查向 HPV 为基础的筛查转变在北欧国家的不同影响。
Eur J Public Health. 2024 Apr 3;34(2):354-360. doi: 10.1093/eurpub/ckad225.
8
Clinical use of the Onclarity test with extended HPV genotyping and phenotyping in patients with suspected squamous intraepithelial lesions.在疑似鳞状上皮内病变患者中,使用 Onclarity 检测进行扩展型 HPV 基因分型和表型分析的临床应用。
Ginekol Pol. 2024;95(5):328-334. doi: 10.5603/gpl.96712. Epub 2023 Dec 15.
9
The Prevalence of High-Risk Human Papillomavirus in Hungary-A Geographically Representative, Cross-Sectional Study.匈牙利高危型人乳头瘤病毒的流行情况:一项具有地理代表性的横断面研究。
Pathol Oncol Res. 2022 Jun 15;28:1610424. doi: 10.3389/pore.2022.1610424. eCollection 2022.
10
[Phased implementation of HPV-based cervical cancer screening in Denmark].[丹麦基于人乳头瘤病毒的宫颈癌筛查分阶段实施情况]
Ugeskr Laeger. 2022 Feb 28;184(9).